Ionis Pharmaceuticals Q3 2026 earnings
Revenue grew 15% YoY driven by commercial and R&D, but GAAP operating loss widened to $102M from a $140M profit.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $268M | +15% | — | Ex. 99.1, income statement |
| EPS (GAAP) | -$0.69 | -88.3% | — | Ex. 99.1, income statement |
| EPS (adjusted) | -$0.70 | -154.5% | — | Ex. 99.1, income statement |
| Net income | -$115M | -192.7% | — | Ex. 99.1, income statement |
| Adj. EBITDA | -$57M | -133.5% | — | Ex. 99.1, income statement |
| Adj. EBITDA margin | -21.3% | -1.2 pp | — | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Commercial revenue | $119M | +15% | 44% | Product sales + Royalties |
| Research and development revenue | $149M | -57% | 56% | Collaborative agreement revenue |
Margins and costs
- Gross margin 1.1% (prior 0.9%, change +0.2 pp)
- Operating expenses $370M (+18.6% YoY)
- One-offs in the quarter Interest expense related to the sale of future royalties: $18M; Interest expense related to the sale of future royalties: $35M (YTD)
- Effective tax rate 0.9% (prior-year 0%, year-to-date 0.5%)
- Non-GAAP bridge Excludes compensation expense related to equity awards and related tax effects. Compensation expense is non-cash.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash, cash equivalents and short-term investments | $2,055M | $2,677M | $2,055M | -$622M |
| Contracts receivable | $59M | $66M | $59M | -$7M |
| Total assets | $2,995M | $3,524M | $2,995M | -$529M |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Revenue | $1.0B - $1.1B | $1.0B - $1.1B | No change |
| Operating expenses | $1.3B - $1.4B | $1.3B - $1.4B | No change |
| Cash, cash equivalents and short-term investments | $2.0B - $2.1B | $2.0B - $2.1B | No change |
What drove it
- Revenue story Commercial revenue grew 15% YoY driven by DAWNZERA product sales; R&D revenue declined 57% YoY due to the absence of a $280M upfront payment received in Q2 2025.
- EPS story GAAP EPS loss widened from $0.78 to -$0.69, primarily due to a $102M GAAP operating loss versus a $140M profit in the prior year.
- One-off check Interest expense related to the sale of future royalties: $18M (Q3 2026) and $35M (YTD 2026).
The good
- Commercial revenue grew 15% YoY driven by DAWNZERA product sales.
- On track to achieve 2026 financial guidance.
The bad
- Research and development revenue declined 57% YoY due to the absence of a $280M upfront payment received in Q2 2025.
- GAAP operating loss widened to $102M from a $140M profit in the prior year.
The ugly
- none
Open questions
- What is the specific impact of the CARDIO-TTRansform study outcome on the eplontersen franchise?
- What is the specific impact of the pelacarsen Lp(a) HORIZON cardiovascular outcomes trial results on the franchise?
- What is the specific impact of the global launch of bepirovirsen for chronic hepatitis B on revenue?
- What is the specific impact of the approval of zilganersen for Alexander disease on the franchise?
Full release
Ionis Pharmaceuticals (IONS) earnings release, November 9, 2026
Attachments
Seq Document Description
───────────────────────────────────────────────────────────────────────────────
2 ef20085128_ex99-1.htm EXHIBIT 99.1
Financial statements
Income Statement
From the 10-Q · Three Months Ended — (Unaudited) (in thousands)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|---|---|
| Commercial revenue: | ||||
| Product sales, net | 48,296 | 32,530 | 122,390 | 58,091 |
| Royalty revenue | 80,592 | 75,694 | 214,874 | 209,811 |
| Other commercial revenue | 7,317 | 7,374 | 25,375 | 26,621 |
| Total commercial revenue | 136,205 | 115,598 | 362,639 | 294,523 |
| Research and development revenue: | ||||
| Collaborative agreement revenue | 102,770 | 31,436 | 356,567 | 413,387 |
| WAINUA joint development revenue | 3,746 | 9,685 | 37,556 | 32,471 |
| Total research and development revenue | 106,516 | 41,121 | 394,123 | 445,858 |
| Total revenue | 242,721 | 156,719 | 756,762 | 740,381 |
| Expenses: | ||||
| Cost of sales | 3,322 | 2,338 | 9,043 | 7,952 |
| Research, development and patent | 215,878 | 217,754 | 643,158 | 635,973 |
| Selling, general and administrative | 154,222 | 96,809 | 454,977 | 263,681 |
| Total operating expenses | 373,422 | 316,901 | 1,107,178 | 907,606 |
| Loss from operations | -130,701 | -160,182 | -350,416 | -167,225 |
| Other income (expense): | ||||
| Investment income | 19,543 | 23,682 | 65,257 | 73,035 |
| Interest expense | -4,628 | -4,212 | -14,405 | -12,434 |
| Interest expense related to sale of future royalties | -4,129 | -17,952 | -38,972 | -55,422 |
| Gain on investments, net | 9,526 | 29,908 | 21,927 | 9,432 |
| Other income, net | 277 | 363 | 805 | 929 |
| Loss before income tax benefit (expense) | -110,112 | -128,393 | -315,804 | -151,685 |
| Income tax benefit (expense) | 141 | -213 | -1,341 | -308 |
| Net loss | -109,971 | -128,606 | -317,145 | -151,993 |
| Basic and diluted net loss per share | -0.66 | -0.8 | -1.92 | -0.95 |
| Shares used in computing basic and diluted net loss per share | 166,205 | 159,765 | 165,504 | 159,216 |
Balance Sheet
From the 10-Q · September 30, — (in thousands, except share data)
| September 30, – 2026 – (unaudited) | December 31, – 2025 | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 296,303 | 372,260 |
| Short-term investments | 1,587,604 | 2,305,176 |
| Contracts receivable | 88,340 | 66,059 |
| Inventories | 28,578 | 10,048 |
| Other current assets | 360,676 | 237,092 |
| Total current assets | 2,361,501 | 2,990,635 |
| Property, plant and equipment, net | 162,059 | 123,048 |
| Right-of-use assets | 228,035 | 238,549 |
| Deposits and other assets | 160,995 | 171,604 |
| Total assets | 2,912,590 | 3,523,836 |
| Current liabilities: | ||
| Accounts payable | 27,113 | 28,082 |
| Accrued compensation | 61,379 | 116,236 |
| Accrued liabilities | 116,177 | 106,089 |
| Income taxes payable | 109 | 2,713 |
| 0 percent convertible senior notes due April 2026, net | 431,948 | |
| Liability related to sale of future royalties, net | 138,188 | 11,689 |
| Current portion of deferred contract revenue | 70,203 | 73,761 |
| Other current liabilities | 22,123 | 11,049 |
| Total current liabilities | 435,292 | 781,567 |
| Long-term deferred contract revenue | 48,755 | 92,001 |
| 0 percent convertible senior notes due 2030, net | 754,289 | 751,495 |
| 1.75 percent convertible senior notes due 2028, net | 569,974 | 567,830 |
| Liability related to sale of future royalties, net | 427,840 | 551,353 |
| Long-term lease liabilities | 262,477 | 262,383 |
| Long-term obligations | 20,323 | 28,118 |
| Total liabilities | 2,518,950 | 3,034,747 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 166,410,425 and 163,304,875 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 166 | 163 |
| Additional paid-in capital | 3,381,632 | 3,145,402 |
| Accumulated other comprehensive loss | -39,818 | -25,281 |
| Accumulated deficit | -2,948,340 | -2,631,195 |
| Total stockholders' equity | 393,640 | 489,089 |
| Total liabilities and stockholders’ equity | 2,912,590 | 3,523,836 |
Cash Flow
From the 10-Q · Nine Months Ended — (Unaudited) (in thousands)
| Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|
| Operating activities: | ||
| Net loss | -317,145 | -151,993 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 10,333 | 6,749 |
| Amortization of right-of-use operating lease assets | 10,514 | 6,803 |
| Amortization of other assets | 2,096 | 1,801 |
| Amortization of discount on investments, net | -12,597 | -18,063 |
| Amortization of debt issuance costs | 6,045 | 4,940 |
| Non-cash royalty revenue related to sale of royalties | -35,986 | -38,478 |